Coenzyme Q10

Educational overview

Dietary supplement, not an FDA-approved wellness medicine; evidence is use-specific and interactions with warfarin and insulin are possible.

Coenzyme Q10 (CoQ10, ubiquinone) is a lipid-soluble benzoquinone that cells synthesize through the mevalonate pathway, the same pathway that produces cholesterol. It carries electrons between complexes of the mitochondrial respiratory chain and, in its reduced form ubiquinol, acts as a membrane antioxidant that limits lipid peroxidation. Tissue concentrations are highest in heart, kidney, and liver, and endogenous synthesis supplies most of what the body holds. Supplements are sold as ubiquinone or ubiquinol in dry-powder capsules, oil suspensions, and solubilised formulations that differ substantially in bioavailability. It is classified as a dietary supplement and mitochondrial cofactor rather than a vitamin, hormone, or peptide.

Human evidence is condition-specific rather than general. Q-SYMBIO, a randomized double-blind trial published in JACC: Heart Failure in 2014, reported fewer major adverse cardiovascular events over two years in chronic heart failure, while a 2021 Cochrane review of coenzyme Q10 for heart failure judged the overall certainty of evidence low and the effect on mortality uncertain. For statin-associated muscle symptoms the literature is openly mixed: a 2015 randomized trial in Atherosclerosis in adults with confirmed statin myopathy found no improvement over placebo, whereas a 2018 meta-analysis in the Journal of the American Heart Association reported reduced muscle pain and weakness across pooled randomized trials. Inherited primary CoQ10 deficiency is the one setting where supplementation is clearly disease-modifying.

In the United States coenzyme Q10 is marketed as a dietary supplement under the Dietary Supplement Health and Education Act. It is not an FDA-approved drug for heart failure, statin myopathy, migraine, fertility, or any other indication, and FDA does not evaluate supplement products for effectiveness before they reach the market. No injectable coenzyme Q10 product has been approved in the United States, so any parenteral preparation is compounded or unapproved, and the oral route carries essentially the whole clinical literature. In the European Union, coenzyme Q10 is a permitted food supplement ingredient with no authorised disease claims, and products remain outside medicines regulation unless a therapeutic claim is made.

Coenzyme Q10 oxidises and is degraded by light, so softgels and capsules are kept in the closed original container at room temperature away from heat and light, with ubiquinol formulations the more fragile of the two. Because absorption is poor from dry powder and better from oil-based or solubilised products, the formulation is a more informative entry in a dose log or inventory record than the milligram figure alone. Brand, lot number, and whether the product supplies ubiquinone or ubiquinol are worth carrying across refills. Concurrent warfarin is the interaction most often flagged, since case reports describe shifts in INR when coenzyme Q10 is started or stopped.

Category

Mitochondrial supplement

Routes represented

Oral

Storage context

Follow the product label; store in the original container away from excess heat and moisture.